Drug regulatory agencies in Germany and Australia have added warnings that atomoxetine can trigger violent or suicidal thoughts—sparking urgent concern over its long‑term use in children and adults.

For comparison, Lilly's arch-rival in the weight-loss category, Novo Nordisk, is developing an oral formulation of GLP-1/amylin agonist amycretin that achieved reductions of between 10.4% and 13.1% in ...

Eli Lilly said on Thursday that its experimental GLP-1 pill helped patients lose 12.4% of their body weight after 72 weeks in ...

Lilly paid $47.5 million upfront to license the non-opioid pain drug candidate CNTX-0290 from Centrexion in 2019. The SSTR4 ...

Novo Nordisk shares surged more than 11% in premarket trading Thursday after Eli Lilly’s data on its oral obesity drug ...

Drugmaker Eli Lilly says their oral, daily GLP-1 pill, orforglipron, may offer similar weight loss results as weekly GLP-1 shots.

Eli Lilly and Company has confirmed it’s selling its 25,000-square-foot manufacturing site in Branchburg. The decision was ...

Shares in Novo Nordisk rose as much as 14% on Thursday after trial data from Eli Lilly's experimental weight-loss pill fell ...

People with obesity who took Eli Lilly's daily oral GLP-1 drug orforglipron lost an average of 12.4% of their body weight, ...

Chief Executive David Ricks said the quarter was marked by robust sales for Zepbound and Mounjaro, in addition to momentum across other key medicines. Eli Lilly logged net income of $5.66 billion, or ...

Shares of Eli Lilly and Co. tumbled 12.8% in premarket trading Thursday, toward its biggest one-day selloff in 26 years, after the drug giant disclosed late-stage trial data for its oral weight-loss ...